Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.

ABSTRACT:

Objective

Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster (HZ), and the risk appears to be increased in patients treated with tofacitinib. The aim of this study was to evaluate whether concomitant treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or glucocorticoids (GCs) contributes to the increased risk of HZ in RA patients treated with tofacitinib.

Methods

HZ cases were identified from the databases of 2 phase I, 9 phase II, 6 phase III, and 2 long-term extension studies of tofacitinib in RA patients. Crude incidence rates (IRs) of all HZ events (serious and nonserious) per 100 patient-years (with 95% confidence intervals [95% CIs]) were calculated for unique patients. Within phase III studies, we describe

SUBMITTER: Winthrop KL 

PROVIDER: S-EPMC5656820 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature